• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

达沙替尼在异基因造血细胞移植后使用与巨细胞病毒再激活的风险。

Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation.

机构信息

Division of Infectious Diseases, Brigham and Women's Hospital.

Division of Medical Oncology, Dana-Farber Cancer Institute.

出版信息

Clin Infect Dis. 2017 Aug 1;65(3):510-513. doi: 10.1093/cid/cix325.

DOI:10.1093/cid/cix325
PMID:28419210
Abstract

Viral infections have been reported with dasatinib use, but its cytomegalovirus risk after hematopoietic-cell transplantation (HCT) is not known. We found that post-HCT dasatinib use increased the risk of cytomegalovirus reactivation (adjusted hazard ratio, 7.65; 95% confidence interval, 1.84-31.7), controlling for acute graft-versus-host disease, in 109 patients with Philadelphia-chromosome-positive malignancies.

摘要

已有报道称达沙替尼的使用与病毒感染相关，但在造血细胞移植（HCT）后使用达沙替尼是否会增加巨细胞病毒再激活的风险尚不清楚。我们发现，在 109 例费城染色体阳性恶性肿瘤患者中，在控制急性移植物抗宿主病的情况下，HCT 后使用达沙替尼会增加巨细胞病毒再激活的风险（调整后的危险比为 7.65；95%置信区间为 1.84-31.7）。

相似文献

1
Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation.达沙替尼在异基因造血细胞移植后使用与巨细胞病毒再激活的风险。
Clin Infect Dis. 2017 Aug 1;65(3):510-513. doi: 10.1093/cid/cix325.
2
Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.异基因造血干细胞移植后巨细胞病毒再激活与移植后存活至第100天的急性髓系白血病患者复发风险降低相关：日本造血细胞移植学会移植相关并发症工作组
Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26.
3
Characteristics of patients with development of large granular lymphocyte expansion among dasatinib-treated patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation.达沙替尼治疗的异基因造血干细胞移植后复发的费城染色体阳性急性淋巴细胞白血病患者中出现大颗粒淋巴细胞扩增的患者特征。
Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):e47-54. doi: 10.1016/j.clml.2014.09.006. Epub 2014 Sep 28.
4
Dasatinib-Induced Colitis after Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.达沙替尼治疗费城染色体阳性急性淋巴细胞白血病异基因干细胞移植后所致结肠炎
Biol Blood Marrow Transplant. 2016 Oct;22(10):1900-1903. doi: 10.1016/j.bbmt.2016.06.022. Epub 2016 Jun 23.
5
CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.异基因造血干细胞移植后巨细胞病毒再激活与复发风险：急性髓系白血病的早期保护证据。
Blood. 2013 Aug 15;122(7):1316-24. doi: 10.1182/blood-2013-02-487074. Epub 2013 Jun 6.
6
Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.达沙替尼诱导费城染色体阳性急性淋巴细胞白血病患儿第二次缓解后成功进行第二次异基因干细胞移植。
Pediatr Blood Cancer. 2009 Jul;52(7):891-2. doi: 10.1002/pbc.21938.
7
Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?酪氨酸激酶抑制剂用于移植后维持治疗能否改善高危费城染色体阳性白血病患者的预后？
Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):466-471.e1. doi: 10.1016/j.clml.2016.04.017. Epub 2016 May 5.
8
Cytomegalovirus infection- and dasatinib-induced proteinuria in Ph+ALL.
Pediatr Int. 2017 Jun;59(6):740-741. doi: 10.1111/ped.13251. Epub 2017 Apr 25.
9
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.达沙替尼：一种用于治疗慢性粒细胞白血病和费城染色体阳性急性淋巴细胞白血病的酪氨酸激酶抑制剂。
Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005.
10
Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with -positive acute lymphoblastic leukemia.达沙替尼和异基因干细胞移植使一名老年B细胞阳性急性淋巴细胞白血病患者获得持续缓解。
Haematologica. 2017 Apr;102(4):e160-e162. doi: 10.3324/haematol.2016.160531. Epub 2017 Jan 5.

引用本文的文献

1
Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients.异体造血细胞移植受者中 posoleucel 的 2 期试验的最终结果。
Blood Adv. 2024 Sep 10;8(17):4740-4750. doi: 10.1182/bloodadvances.2023011562.
2
The ageing immune system as a potential target of senolytics.衰老的免疫系统作为衰老细胞溶解剂的潜在靶点。
Oxf Open Immunol. 2023 May 3;4(1):iqad004. doi: 10.1093/oxfimm/iqad004. eCollection 2023.
3
Cytomegalovirus US28 regulates cellular EphA2 to maintain viral latency.巨细胞病毒US28调节细胞EphA2以维持病毒潜伏状态。
Sci Adv. 2022 Oct 28;8(43):eadd1168. doi: 10.1126/sciadv.add1168. Epub 2022 Oct 26.
4
Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial.索拉非尼维持治疗对 FLT3-ITD AML 患者异基因造血干细胞移植后 EBV 和 CMV 感染的影响：一项随机临床试验的二次分析。
BMC Med. 2022 Sep 2;20(1):282. doi: 10.1186/s12916-022-02479-x.
5
The Interaction of Viruses with the Cellular Senescence Response.病毒与细胞衰老反应的相互作用。
Biology (Basel). 2020 Dec 9;9(12):455. doi: 10.3390/biology9120455.
6
Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: Practical Considerations and Lessons to Be Learned.2019冠状病毒病大流行期间血液系统恶性肿瘤患者的管理：实际考量与经验教训
Front Oncol. 2020 Aug 14;10:1439. doi: 10.3389/fonc.2020.01439. eCollection 2020.
7
Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation.同种异体干细胞移植后巨细胞病毒感染的细胞治疗方法。
Front Immunol. 2020 Jul 31;11:1694. doi: 10.3389/fimmu.2020.01694. eCollection 2020.
8
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.生物制剂和小分子靶向免疫调节治疗的感染并发症。
Clin Microbiol Rev. 2020 Jun 10;33(3). doi: 10.1128/CMR.00035-19. Print 2020 Jun 17.
9
Acute leukemia in the time of COVID-19.新冠疫情期间的急性白血病
Leuk Res. 2020 Mar 26;92:106353. doi: 10.1016/j.leukres.2020.106353.
10
Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation.巨细胞病毒再激活对造血干细胞移植中非复发死亡率的异质性影响。
Blood Adv. 2020 Mar 24;4(6):1051-1061. doi: 10.1182/bloodadvances.2019000814.